Chromadex (NASDAQ:CDXC)‘s stock had its “buy” rating reiterated by HC Wainwright in a report released on Monday. They currently have a $8.00 target price on the stock. HC Wainwright’s target price suggests a potential upside of 128.57% from the stock’s previous close.

The analysts wrote, “Valuation methodology, risks and uncertainties. We apply a 24x EV- to-EBITDA multiple to 2020 EBITDA per share of $0.45, discounted back at 12%, which yields a price objective of approximately $8.00 per share.””

Other analysts have also recently issued research reports about the company. Zacks Investment Research upgraded Chromadex from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 24th. BidaskClub cut Chromadex from a “hold” rating to a “sell” rating in a research report on Friday, August 24th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. Chromadex presently has an average rating of “Hold” and a consensus price target of $7.50.

NASDAQ:CDXC opened at $3.50 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.24 and a quick ratio of 3.65. Chromadex has a 12-month low of $3.19 and a 12-month high of $7.24. The stock has a market cap of $215.82 million, a P/E ratio of -10.00 and a beta of 1.32.

Chromadex (NASDAQ:CDXC) last released its earnings results on Thursday, August 9th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Chromadex had a negative return on equity of 65.33% and a negative net margin of 82.82%. The business had revenue of $7.80 million for the quarter, compared to analysts’ expectations of $7.50 million. research analysts anticipate that Chromadex will post -0.54 EPS for the current year.

Large investors have recently added to or reduced their stakes in the stock. Deutsche Bank AG grew its position in shares of Chromadex by 31,769.4% during the fourth quarter. Deutsche Bank AG now owns 22,946 shares of the company’s stock worth $134,000 after purchasing an additional 22,874 shares in the last quarter. Rhumbline Advisers bought a new position in Chromadex during the second quarter valued at approximately $118,000. Element Capital Management LLC bought a new position in Chromadex during the first quarter valued at approximately $155,000. GSA Capital Partners LLP bought a new position in Chromadex during the second quarter valued at approximately $193,000. Finally, Northern Trust Corp boosted its stake in Chromadex by 34.4% during the first quarter. Northern Trust Corp now owns 55,902 shares of the company’s stock valued at $235,000 after buying an additional 14,297 shares during the last quarter. Hedge funds and other institutional investors own 16.24% of the company’s stock.

Chromadex Company Profile

ChromaDex Corporation operates as a nutraceutical company. The company offers research and quality control products and services to dietary supplements, food, beverages, cosmetic, and pharmaceutical industries; Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide(NAD) level used for healthy aging; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients.

See Also: Stop Order Uses For Individual Investors

Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.